Home Finance Nasdaq-listed Sonnet BioTherapeutics agrees to $888 million merger to become Hyperliquid Strategies, launch HYPE treasury 6 months ago 6 months ago Nasdaq-listed Sonnet BioTherapeutics agrees to $888 million merger to become Hyperliquid Strategies, launch HYPE treasury by James Hunt 6 months ago6 months ago Hyperliquid Strategies is expected to hold 12.6 million HYPE tokens and $305 million in cash at closing of the deal. Source link Post PaginationPrevious PostPreviousNext PostNext